Related references
Note: Only part of the references are listed.Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Estela Pineda et al.
ONCOTARGETS AND THERAPY (2023)
Exosomes derived from rapamycin-treated 4T1 breast cancer cells induced polarization of macrophages to M1 phenotype
Majdedin Ghalavand et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2023)
Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering
Ke Si et al.
CYTOTHERAPY (2023)
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Lauren R. Schaff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy
Seyyed Hossein Khatami et al.
MOLECULAR NEUROBIOLOGY (2023)
Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment
Maxim Sidorov et al.
CELLS (2023)
Personalised therapeutic approaches to glioblastoma: A systematic review
Oliver D. Mowforth et al.
FRONTIERS IN MEDICINE (2023)
Personalized Treatment of Glioblastoma: Current State and Future Perspective
Alen Roncevic et al.
BIOMEDICINES (2023)
Expression of mTOR in normal and pathological conditions
A. Marques-Ramos et al.
MOLECULAR CANCER (2023)
Glioblastoma cell-derived exosomes functionalized with peptides as efficient nanocarriers for synergistic chemotherapy of glioblastoma with improved biosafety
Ying Zhou et al.
NANO RESEARCH (2023)
Sirolimus-loaded exosomes as a promising vascular delivery system for the prevention of post-angioplasty restenosis
Fatemeh Mehryab et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2023)
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment
Shilpi Singh et al.
BIOMEDICINES (2023)
Challenges in glioblastoma research: focus on the tumor microenvironment
Andreas Bikfalvi et al.
TRENDS IN CANCER (2023)
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
Fatima Khan et al.
JOURNAL OF CLINICAL INVESTIGATION (2023)
Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors
Joo Hang Lee et al.
ACTA BIOMATERIALIA (2022)
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
Amir Barzegar Behrooz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
HIV-1 hypermethylated guanosine cap licenses specialized translation unaffected by mTOR
Gatikrushna Singh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3
Shi-Fu Liang et al.
BIOMATERIALS SCIENCE (2022)
AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma
Eslam E. Abd El-Fattah et al.
FRONTIERS IN PHARMACOLOGY (2022)
Development of a novel rapamycin loaded nano- into micro-formulation for treatment of lung inflammation
Emanuela Fabiola Craparo et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Sahar Mafi et al.
FRONTIERS IN IMMUNOLOGY (2022)
Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
Hui Liu et al.
ACTA PHARMACEUTICA SINICA B (2022)
A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy
Miao Fan et al.
BIOMATERIALS (2022)
Development of rapamycin-encapsulated exosome-mimetic nanoparticles-in-PLGA microspheres for treatment of hemangiomas
Haitao Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Marsel Khabibov et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2022)
Emerging therapies for glioblastoma: current state and future directions
Liang Rong et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity
Peng Bao et al.
NANO LETTERS (2022)
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications
Esraa Mohamed et al.
NEURO-ONCOLOGY (2022)
Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer
Tianyao Liu et al.
CANCER MEDICINE (2022)
Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy
Boyan Li et al.
ADVANCED SCIENCE (2022)
Therapeutic Effect of Rapamycin-Loaded Small Extracellular Vesicles Derived from Mesenchymal Stem Cells on Experimental Autoimmune Uveitis
Huan Li et al.
FRONTIERS IN IMMUNOLOGY (2022)
Epidemiology of Glioblastoma Multiforme-Literature Review
Szymon Grochans et al.
CANCERS (2022)
Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment
Soghra Bagheri et al.
PHARMACEUTICS (2022)
Tumour-derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour-homing and intracellular freeway transportation
Xin Zhou et al.
JOURNAL OF EXTRACELLULAR VESICLES (2022)
The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression
Filippo Torrisi et al.
BIOMEDICINES (2022)
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma
Elisabeth Rackles et al.
SEMINARS IN CANCER BIOLOGY (2022)
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment
Ruoning Wang et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2022)
Lapatinib loaded exosomes as a drug delivery system in breast cancer
Nurdan Sena Degirmenci et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2022)
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Eunus S. Ali et al.
CANCER CELL INTERNATIONAL (2022)
mTORC1 beyond anabolic metabolism: Regulation of cell death
Jiajun Zhu et al.
JOURNAL OF CELL BIOLOGY (2022)
Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
Iris Dive et al.
CELL DEATH DISCOVERY (2022)
Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges
Yubo Zhang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2022)
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity
Sushrut Kamerkar et al.
SCIENCE ADVANCES (2022)
A review of glioblastoma immunotherapy
Ravi Medikonda et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling
Yu-Kai Su et al.
PHARMACEUTICALS (2021)
Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy
Jingjing Ding et al.
ADVANCED MATERIALS (2021)
Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma
Jessica Guenzle et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Nadezhda V. Popova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
A Review of Newly Diagnosed Glioblastoma
Bryan Oronsky et al.
FRONTIERS IN ONCOLOGY (2021)
Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery
Tin Chanh Pham et al.
JOURNAL OF EXTRACELLULAR VESICLES (2021)
Rapamycin-Loaded Lipid Nanocapsules Induce Selective Inhibition of the mTORC1-Signaling Pathway in Glioblastoma Cells
Delphine Sehedic et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
Lin Tang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
Mayra Colardo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Benjamin T. Himes et al.
FRONTIERS IN ONCOLOGY (2021)
The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
Kostas A. Papavassiliou et al.
BIOMEDICINES (2021)
Apoptotic body-mediated intercellular delivery for enhanced drug penetration and whole tumor destruction
Dongyang Zhao et al.
SCIENCE ADVANCES (2021)
Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
Alexandre el Hage et al.
CANCERS (2021)
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
Shaolu Zhang et al.
CELL DEATH & DISEASE (2021)
Regulation of human mTOR complexes by DEPTOR
Matthias Waelchli et al.
ELIFE (2021)
Exosomes as Naturally Occurring Vehicles for Delivery of Biopharmaceuticals: Insights from Drug Delivery to Clinical Perspectives
Arun Butreddy et al.
NANOMATERIALS (2021)
Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches
Eilam Yeini et al.
ADVANCED THERAPEUTICS (2021)
Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells
Jing Bai et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation
Christian Boada et al.
CIRCULATION RESEARCH (2020)
Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes
Gyeungyun Kim et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis
Liuwan Zhao et al.
JOURNAL OF CONTROLLED RELEASE (2020)
MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway
Guohua Lou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
mTOR at the nexus of nutrition, growth, ageing and disease
Grace Y. Liu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation
Zhaogang Yang et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma
Kazuki Kuroshima et al.
CANCER SCIENCE (2020)
Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer
Gaofeng Liang et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems
Natalia N. Ferreira et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2020)
The mRNA encoding the JUND tumor suppressor detains nuclear RNA-binding proteins to assemble polysomes that are unaffected by mTOR
Gatikrushna Singh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou et al.
CELL AND BIOSCIENCE (2020)
The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells
Xiaohui Zhang et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2020)
Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment
Anaelle A. Dumas et al.
EMBO JOURNAL (2020)
Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy
Jialang Zhuang et al.
NUCLEIC ACIDS RESEARCH (2020)
Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
Qin Xia et al.
FRONTIERS IN ONCOLOGY (2020)
Combined PI3Kα-mTOR Targeting of Glioma Stem Cells
Frank D. Eckerdt et al.
SCIENTIFIC REPORTS (2020)
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
Yangzhi Qi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Reverse Signaling by MHC-I Molecules in Immune and Non-Immune Cell Types
Elke M. Muntjewerff et al.
FRONTIERS IN IMMUNOLOGY (2020)
Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model
Kyeongsoo Jeong et al.
LAB ON A CHIP (2020)
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration
Jing Jin et al.
THERANOSTICS (2020)
mTOR Is Key to T Cell Transdifferentiation
Jiawei Yan et al.
CELL METABOLISM (2019)
Folliculin regulates mTORC1/2 and WNT pathways in early human pluripotency
J. Mathieu et al.
NATURE COMMUNICATIONS (2019)
Role of Notch Signaling Pathway in Glioblastoma Pathogenesis
Riccardo Bazzoni et al.
CANCERS (2019)
Ultrasound Facilitates Naturally Equipped Exosomes Derived from Macrophages and Blood Serum for Orthotopic Glioma Treatment
Lianmei Bai et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma
James Mooney et al.
WORLD NEUROSURGERY (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
EGFR and mTOR as therapeutic targets in glioblastoma
Michael W. Ronellenfitsch et al.
Oncotarget (2019)
Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme
Zachary Gersey et al.
WORLD NEUROSURGERY (2019)
Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: Optimization of formulation variables and in vitro anti-glioma assessment
Oscar Escalona-Rayo et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2019)
Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy
Chunai Gong et al.
JOURNAL OF NANOBIOTECHNOLOGY (2019)
Rapamycin for longevity: opinion article
Mikhail V. Blagosklonny
AGING-US (2019)
mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma
Kenta Masui et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice
M. Garofalo et al.
JOURNAL OF CONTROLLED RELEASE (2019)
mTOR as a central hub of nutrient signalling and cell growth
Joungmok Kim et al.
NATURE CELL BIOLOGY (2019)
Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design
Jigar Vanza et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2018)
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Andreas Wicki et al.
EUROPEAN JOURNAL OF CANCER (2018)
A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer
Yan Li et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
mTOR inhibition in glioblastoma: requiem for a dream?
Sam Babak et al.
NEURO-ONCOLOGY (2018)
Current Challenges and Opportunities in Treating Glioblastoma
Andrea Shergalis et al.
PHARMACOLOGICAL REVIEWS (2018)
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Fabiana Conciatori et al.
CANCERS (2018)
Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance
Evan K. Noch et al.
WORLD NEUROSURGERY (2018)
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
Carmen Mecca et al.
DISEASE MARKERS (2018)
Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity
Qnqin Cheng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Exosomes as drug carriers for clinical application
Cuixia Di et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection
Sahar Salehi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
Seung Min Kim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Hua-fu Zhao et al.
MOLECULAR CANCER (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity
Woelsung Yi et al.
NATURE COMMUNICATIONS (2017)
Covalent modification of pericardial patches for sustained rapamycin delivery inhibits venous neointimal hyperplasia
Hualong Bai et al.
SCIENTIFIC REPORTS (2017)
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Inan Olmez et al.
CLINICAL CANCER RESEARCH (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment
Sameer S. Katiyar et al.
DRUG DELIVERY (2016)
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Shuyang Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
I. A. Netland et al.
BMC CANCER (2016)
4E-BP1, a multifactor regulated multifunctional protein
Xiaoyu Qin et al.
CELL CYCLE (2016)
Cell type-specific control of protein synthesis and proliferation by FGF-dependent signaling to the translation repressor 4E-BP
Rachel Ruoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Timothy P. Heffron et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis model
N-T. Cheng et al.
BONE & JOINT RESEARCH (2016)
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
Zhiyun Yu et al.
CANCER LETTERS (2015)
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma
Kyle T. Householder et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Targeted therapy of colorectal neoplasia with rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles
Supang Khondee et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells
Heikki Saari et al.
JOURNAL OF CONTROLLED RELEASE (2015)
miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients
Johnny C. Akers et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Sylvie M. Guichard et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Curcumin Modulates Pancreatic Adenocarcinoma Cell-Derived Exosomal Function
Carlos J. Diaz Osterman et al.
PLOS ONE (2015)
Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells
Wei Tian et al.
JOURNAL OF MATERIALS CHEMISTRY B (2015)
mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
Huiyuan Zhang et al.
APOPTOSIS (2015)
Co-delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation
Shutao Guo et al.
ACS NANO (2014)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus
Naba Elsaid et al.
EXPERIMENTAL EYE RESEARCH (2014)
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Jenna Kahn et al.
NEURO-ONCOLOGY (2014)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
Shuyu Li et al.
CANCER CELL INTERNATIONAL (2013)
Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth
Mark Katakowski et al.
CANCER LETTERS (2013)
Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth
Arda Mizrak et al.
MOLECULAR THERAPY (2013)
Coibamide A Induces mTOR-Independent Autophagy and Cell Death in Human Glioblastoma Cells
Andrew M. Hau et al.
PLOS ONE (2013)
Enhanced solubility and oral absorption of sirolimus using D-α-tocopheryl polyethylene glycol succinate micelles
Min-Soo Kim et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2013)
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis
Maria Comas et al.
AGING-US (2012)
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
A. Naing et al.
BRITISH JOURNAL OF CANCER (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Abstract B146: XL388: A novel, selective, orally bioavailable mTORC1 and mTORC2 inhibitor that demonstrates pharmacodynamic and antitumor activity in multiple human cancer xenograft models
N. Miller
MOLECULAR CANCER THERAPEUTICS (2012)
Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG
Jason R. Hasenstein et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Clinicopathological significance of cathepsin D expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study
Chuifeng Fan et al.
TUMOR BIOLOGY (2012)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
Bipasha Mukherjee et al.
NEOPLASIA (2012)
Positively Charged Amphiphilic Chitosan Derivative for the Transscleral Delivery of Rapamycin
Naba Elsaid et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
George J. Cerniglia et al.
MOLECULAR PHARMACOLOGY (2012)
Rapamycin-Loaded Nanoparticles for Inhibition of Neointimal Hyperplasia in Experimental Vein Grafts
Junjie Zou et al.
ANNALS OF VASCULAR SURGERY (2011)
A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models
Tugba Bagci-Onder et al.
CANCER RESEARCH (2011)
Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival
Karen Y. Dane et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Poly(ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonyl-propylene Carbonate) Micelles for Rapamycin Delivery: In Vitro Characterization and Biodistribution
Wenli Lu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells
Jun Sunayama et al.
NEURO-ONCOLOGY (2010)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Ker Yu et al.
CANCER RESEARCH (2009)
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Christine M. Hartford et al.
CLINICAL CANCER RESEARCH (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
M-A Westhoff et al.
ONCOGENE (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Beth Apsel et al.
NATURE CHEMICAL BIOLOGY (2008)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)